Turning Point Therapeutics Appoints Dr. Robert Xin as Senior Vice President of Clinical Development

Turning Point Therapeutics, Inc., a clinical-stage precision oncology
company developing novel drugs that address treatment resistance, today
announced the appointment of Robert (Xiaohua) Xin, M.D., Ph.D., as
senior vice president of clinical development.

“With our lead asset advancing toward a registration study and our
pipeline assets progressing through IND enabling studies, Robert joins
our team at the perfect time with excellent experience to help guide our
programs,” said Athena Countouriotis, M.D., chief executive officer.
“Our team is growing and with each new hire I am pleased we are
attracting talented and passionate leaders, like Robert, who bring the
experience and patient commitment to help ensure our continued success.”

Dr. Xin has more than 20 years of oncology drug discovery and clinical
development experience in biotech and large biopharma companies for
indications in solid tumors and hematologic malignancies, in a variety
of therapeutic modalities. For the past 6 years, he has served in
positions of increasing leadership responsibility at Pfizer, most
recently as interim vice president of oncology clinical development.
Before Pfizer, Dr. Xin served for 7 years at Roche/Genentech in senior
oncology clinical development roles. His early career experience
includes drug discovery, development and translational medicine roles at
Chiron, Eli Lilly and Sugen. His extensive experience includes multiple
successful drug approvals, companion diagnostic development, regulatory
and clinical strategy and organizational leadership.

“The Turning Point Therapeutics team has developed an impressive
pipeline of kinase inhibitors with encouraging pre-clinical and clinical
results,” said Dr. Xin. “I look forward to contributing to the
development of these assets and ultimately making a difference in the
lives of patients who develop resistance to conventional
kinase-inhibitor therapies.”

Dr. Xin earned his M.D. and M.S. in Pharmacology degrees from the
Zhejiang University School of Medicine in China. In addition, he earned
a Ph.D. in Cell and Molecular Physiology from the University of North
Carolina at Chapel Hill School of Medicine.

About Turning Point Therapeutics Inc.

Turning Point Therapeutics is a clinical-stage precision oncology
company with a pipeline of internally discovered investigational drugs
designed to address key limitations of existing cancer therapies. The
company’s lead program, repotrectinib, is a next-generation kinase
inhibitor targeting genetic drivers of non-small cell lung cancer and
advanced solid tumors. Repotrectinib has shown antitumor activity and
durable responses among kinase-naïve and pre-treated patients, and is
expected to enter a registrational study in the second half of 2019.
Turning Point’s kinase inhibitors are designed to bind to their targets
with greater precision and affinity than existing therapies, with a
novel, compact structure that has demonstrated an ability to overcome
treatment resistance common in other kinase inhibitors. The company is
driven to develop therapies that mark a turning point for patients in
their cancer treatment. For more information, visit www.tptherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190128005086/en/